1034 completed, 252 recruiting, 228 unknown, 196 terminated. 697 Phase 2, 615 Phase 1, 292 Not applicable, 241 Phase 3, 56 Phase 4.
Follow Tumor Virus Infections: new trials by email Literature Review of Tumor Virus Infections trials Research Report on Tumor Virus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM - Common Wart | Phase 2 | Suspended | G&E Herbal Biotechnology Co., LTD | 102 | 2030-09-01 | 2023-09-14 |
| Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone - Human Papillomavirus (HPV) Vaccines | Not applicable | Not yet recruiting | University of Florida | 1296 | 2027-09-15 | 2026-09-14 |
| Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With Human Papillomavirus (HPV) Papilozumib vaginal gel, Papilozumib oral supplement - Human Papillomavirus Infection, Human Papillomavirus Infections | Not applicable | Not yet recruiting | Hifas da Terra S.L. | 81 | 2027-07-01 | 2026-10-05 |
| Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men Cytology Specimen Collection Procedure, High Resolution Anoscopy with Biopsy, Laboratory Biomarker Analysis - HIV Infection, Human Papillomavirus Infection | Withdrawn | AIDS Malignancy Consortium | 2027-04-30 | 2025-06-06 | ||
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults MVA-BN-EBV, Placebo - Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Bavarian Nordic | 15 | 2026-12-15 | 2026-10-22 |
| Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia Rituximab - PTLD, Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Jennifer Amengual | 28 | 2026-12-01 | 2026-09-17 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases Donor-derived ex-vivo expanded EBV Tscm CTL - EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 10 | 2026-11-01 | 2025-03-03 |
| 25BT056: Basket Study of Viral Cytotoxic T Lymphocytes Virus-Specific Cytotoxic T Lymphocytes (vCTLs) - EBV Viremia, CMV Viremia | Early Phase 1 | Not yet recruiting | Children's Hospital of Philadelphia | 35 | 2026-11-01 | 2026-10-22 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) PRGN-2012, Bevacizumab - Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV) | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 50 | 2026-10-28 | 2026-10-23 |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-28 | 2026-10-23 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108) V503, Placebo - Papillomavirus Infections | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 930 | 2026-10-10 | 2026-10-22 |
Showing 20 of 2035. Sign in to see all of them.
Burkitt Lymphoma (972) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (585) · Lymphoma, Large B-Cell, Diffuse (576) · Papillomavirus Infections (562) · Lymphoma, Follicular (522) · Lymphoma, Mantle-Cell (509) · Lymphoma, Non-Hodgkin (503) · Leukemia, Lymphocytic, Chronic, B-Cell (464) · Lymphoma, B-Cell, Marginal Zone (458) · Lymphoma (453) · Lymphoma, Large-Cell, Immunoblastic (445) · Hodgkin Disease (354) · Leukemia (267) · Lymphoma, T-Cell, Cutaneous (255) · Leukemia, Myeloid, Acute (253)
DNA Virus Infections (2026) · Virus Diseases (2010) · Infections (1977) · Neoplasms (1380) · Pathological Conditions, Signs and Symptoms (1282) · Pathologic Processes (1275) · Disease Attributes (1230) · Neoplasms by Histologic Type (1200) · Herpesviridae Infections (1144) · Immune System Diseases (1105) · Hemic and Lymphatic Diseases (1038) · Lymphatic Diseases (1034) · Immunoproliferative Disorders (1025) · Lymphoproliferative Disorders (984)
Cyclophosphamide (238) · Rituximab (120) · Etoposide (107) · Methotrexate (96) · Vincristine (95) · Filgrastim (94) · Peripheral Blood Stem Cell Transplantation (94) · Cytarabine (93) · fludarabine phosphate (89) · Radiotherapy (78) · Doxorubicin (73) · Prednisone (71) · Dexamethasone (62) · fludarabine (54) · Cyclosporine (53)
National Cancer Institute (NCI) (148) · GlaxoSmithKline (72) · Fred Hutchinson Cancer Center (64) · Merck Sharp & Dohme LLC (54) · M.D. Anderson Cancer Center (40) · Memorial Sloan Kettering Cancer Center (32) · City of Hope Medical Center (28) · Children's Oncology Group (25) · Masonic Cancer Center, University of Minnesota (25) · Case Comprehensive Cancer Center (23) · Mayo Clinic (21) · National Institute of Allergy and Infectious Diseases (NIAID) (19) · University of Washington (19) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (18) · Baylor College of Medicine (17)
United States (1126) · China (217) · Canada (110) · France (105) · Italy (83) · Australia (73) · Germany (73) · Spain (67) · United Kingdom (67) · Belgium (51) · Netherlands (36) · Puerto Rico (36) · Taiwan (35) · South Korea (34) · Switzerland (34)
Ajay Gopal (9) · Elias Jabbour (7) · Helen E Heslop, MD (6) · Philip L. McCarthy, MD (6) · Christos E. Emmanouilides, MD (5) · David Maloney (5) · Elias Jabbour, MD (5) · Ibrahim Aldoss (5) · Joel Palefsky, MD (5) · Jun Zhang, Master (5) · Roger Strair, MD, PhD (5)
PMID 41276263, PMID 41671463, PMID 35622074, PMID 34515338, PMID 27422279, PMID 32499241, PMID 19935017, PMID 32184277, PMID 31824976, PMID 19236277, PMID 19236279, PMID 24731816, PMID 25424785, PMID 25424918, PMID 29074187, PMID 29211620, PMID 30982556, PMID 32589970, PMID 33857679, PMID 35149535, PMID 38551807, PMID 41166720, PMID 15897380, PMID 17242396, PMID 17628649, PMID 18515521, PMID 19586656, PMID 19949018, PMID 20028764, PMID 20949623, PMID 21471141, PMID 21527516, PMID 22002018, PMID 22265115, PMID 22337718, PMID 22454089, PMID 23066159, PMID 23299013, PMID 23336207, PMID 23632723, PMID 24862638, PMID 25057165, PMID 25273231, PMID 25424783, PMID 27566633, PMID 29214505, PMID 29269325, PMID 29767739, PMID 29995724, PMID 31464859
P30CA015704 (25), P30CA033572 (24), P30CA043703 (18), U10CA032102 (17), P30CA006973 (14), P30CA015083 (12), U01CA121947 (12), U10CA180886 (12), P30CA022453 (11), 2018 (10), 2023 (10), 2016 (9), P30CA016672 (9), P30CA072720 (9), U01CA097452 (9)